Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Proto Oncogene Tyrosine Protein Kise Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Overview
Proto Oncogene Tyrosine Protein Kise Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Proto Oncogene Tyrosine Protein Kise Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Proto Oncogene Tyrosine Protein Kise Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Companies Involved in Therapeutics Development
AbbVie Inc
AstraZeneca Plc
Avalyn Pharma Inc
Boehringer Ingelheim Intertiol GmbH
Chengdu Fanxi Biopharma Co Ltd
Fratagene Therapeutics Srl
KeifeRx LLC
Lead Discovery Center GmbH
nocopoeia LLC
Prous Institute for Biomedical Research SA
Taiwan Liposome Co Ltd
Turning Point Therapeutics Inc
Proto Oncogene Tyrosine Protein Kise Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Drug Profiles
bosutinib - Drug Profile
Product Description
Mechanism Of Action
History of Events
dasatinib - Drug Profile
Product Description
Mechanism Of Action
History of Events
Drugs to Inhibit SRC for Friedreich Ataxia - Drug Profile
Product Description
Mechanism Of Action
FNX-006 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ilorasertib - Drug Profile
Product Description
Mechanism Of Action
History of Events
JRP-890 - Drug Profile
Product Description
Mechanism Of Action
nintedanib - Drug Profile
Product Description
Mechanism Of Action
History of Events
nintedanib - Drug Profile
Product Description
Mechanism Of Action
History of Events
Ofev - Drug Profile
Product Description
Mechanism Of Action
History of Events
repotrectinib - Drug Profile
Product Description
Mechanism Of Action
History of Events
saracatinib difumarate - Drug Profile
Product Description
Mechanism Of Action
History of Events
Si-306 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Inhibit IGF1R and SRC for Non-Small Cell Lung Cancer - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Inhibit SRC for Oncology - Drug Profile
Product Description
Mechanism Of Action
History of Events
TPX-0022 - Drug Profile
Product Description
Mechanism Of Action
History of Events
TPX-0046 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Vargatef - Drug Profile
Product Description
Mechanism Of Action
History of Events
Proto Oncogene Tyrosine Protein Kise Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Dormant Products
Proto Oncogene Tyrosine Protein Kise Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Discontinued Products
Proto Oncogene Tyrosine Protein Kise Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Product Development Milestones
Featured News & Press Releases
Feb 17, 2022: Zai Lab announces breakthrough therapy desigtion granted for Repotrectinib in Chi
Feb 15, 2022: Boehringer Ingelheim Cada and the pan-Cadian Pharmaceutical Alliance (pCPA) complete negotiations for OFEV (nintedanib) for PF-ILD
Jan 20, 2022: Turning Point Therapeutics announces FDA clearance of investigatiol new drug (IND) application for combition of elzovantinib and aumolertinib in EGFR mutant met-amplified non-small cell lung Cancer
Oct 23, 2021: Turning Point Therapeutics presents early clinical data for Repotrectinib from care study in pediatric and young adult patients at SIOP 2021 Virtual Congress
Oct 13, 2021: Turning Point Therapeutics and EQRx announce clinical collaboration to evaluate elzovantinib in combition with aumolertinib in patients with EGFR mutant met-amplified advanced non-small cell lung cancer
Oct 11, 2021: Turning Point Therapeutics to present early clinical data for repotrectinib from the CARE study in pediatric and young adult patients at SIOP 2021 Virtual Congress
Oct 08, 2021: Turning Point Therapeutics presents TRIDENT-1 study clinical data for repotrectinib in NTRK+ advanced solid tumors in plery session at 2021 AACR-NCI-EORTC Conference
Oct 04, 2021: Turning Point Therapeutics granted Breakthrough Therapy Desigtion for Repotrectinib treatment in patients with NTRK-positive, TKI-pretreated advanced solid tumors
Sep 30, 2021: Turning Point Therapeutics announces additiol details for three data presentations at the 2021 AACR-NCI-EORTC conference
Sep 08, 2021: Turning Point Therapeutics announces early clinical data for Repotrectinib in NTRK fusion-positive advanced solid tumors selected for late-breaker plery presentation at 2021 AACR-NCI-EORTC conference
Aug 16, 2021: Turning Point Therapeutics initiates TRIDENT-2 clinical study investigating Repotrectinib-Trametinib combition in KRAS G12D mutated advanced solid tumors
Aug 11, 2021: Turning Point Therapeutics granted sixth regulatory desigtion for Repotrectinib
Jun 17, 2021: Turning Point Therapeutics granted FDA Orphan Drug Desigtion for TPX-0022 in gastric cancer
May 28, 2021: Zai Lab announces first patient treated in Chi in the registratiol phase 2 TRIDENT-1 study of repotrectinib
May 14, 2021: Study alysis available during ATS 2021 supports long-term treatment with Ofev in patients with systemic sclerosis-associated interstitial lung disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products under Development by Indications, 2022 (Contd..1)
Number of Products under Development by Indications, 2022 (Contd..2)
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Companies, 2022 (Contd..3)
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by AbbVie Inc, 2022
Pipeline by AstraZeneca Plc, 2022
Pipeline by Avalyn Pharma Inc, 2022
Pipeline by Boehringer Ingelheim International GmbH, 2022
Pipeline by Chengdu Fanxi Biopharma Co Ltd, 2022
Pipeline by Fratagene Therapeutics Srl, 2022
Pipeline by KeifeRx LLC, 2022
Pipeline by Lead Discovery Center GmbH, 2022
Pipeline by Nanocopoeia LLC, 2022
Pipeline by Prous Institute for Biomedical Research SA, 2022
Pipeline by Taiwan Liposome Co Ltd, 2022
Pipeline by Turning Point Therapeutics Inc, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Dormant Products, 2022 (Contd..2)
Dormant Products, 2022 (Contd..3)
Discontinued Products, 2022